Jason P. Rhodes, Director at Dyne Therapeutics, Inc. (DYN), sold 504,695 shares at $21.28 ($10.7M) on 2026-06-26, disclosed to the SEC on 2026-06-30.
Scheduled sale ($10.7M) by Director under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $21.28 | 64,411 | $1.4M | 12.8% |
| 2 | $21.28 | 81,903 | $1.7M | 16.3% |
| 3 | $21.28 | 162,954 | $3.5M | 32.4% |
| 4 | $21.14 | 40,702 | $860K | 8.0% |
| 5 | $21.14 | 51,756 | $1.1M | 10.2% |
| 6 | $21.14 | 102,969 |
| $2.2M |
| 20.3% |
| Total | $21.23 avg | 504,695 | $10.7M | 100% |
| Filing → |
| DYN | SELL | 2026-06-26 | $5.6M | — | Filing → |
| DYN | SELL | 2026-05-06 | $1.9M | — | Filing → |
| DYN | SELL | 2026-04-30 | $4.2M | — | Filing → |